<DOC>
	<DOCNO>NCT02690103</DOCNO>
	<brief_summary>Current treatment Hepatitis C virus ( HCV ) severe side effect expensive . There need explore effective natural therapy HCV less toxic cost-effective . 37 chronic HCV infect patient randomize two group treat PEG interferon plus ribavirin first group Biobran , arabinoxylan rice bran ( 1 g/day ) second group . Viremia level , liver enzymes , γ-interferon ( IFN-γ ) level serum , toxicity check three month treatment .</brief_summary>
	<brief_title>Response Modifier ( Arabinoxylan Rice Bran/MGN-3/Biobran ) With Interferon-Alpha HCV</brief_title>
	<detailed_description>The current study preliminary investigation whether Biobran ability restrict viremia patient chronic HCV . In addition , examine effect Biobran liver enzymes inflammation well assess side effect Biobran . Results show treatment Biobran result significant reduction viral load , increase liver enzyme , patient report good health . For randomized trial , select 37 patient admitted El-Kasr El-Aini Hospital Cairo , Egypt . The patient diagnose genotype 4 HCV infection . The study approve Cairo University Hospital , Cairo , Egypt IRB Charles Drew school medicine Science , Los Angeles , CA , USA . The study protocol conform ethical guideline 1975 Declaration Helsinki reflect prior approval Cairo University , El-Kasr El-Aini Hospital , Cairo , Egypt Institutional Review Board ( IRB ) Cairo University , Egypt Charles R Drew University ( CDU ) , Los Angeles , CA. , USA . Thirty-seven patient sex ( 23 male 14 female ) HCV ( genotype 4 ) , age 15 69 , participate current study . Informed consent obtain participant . The patient divide randomly two group : Biobran group PEG interferon plus ribavirin ( control ) group . Prior treatment , clinical characteristic determine patient group . The clinical characteristic HCV patient investigate hepatitis C , alpha-fetoprotein ( AFP ) level , total leucocyte count ( TLC ) , Platelet ( PLT ) count , Hemoglobin ( Hb ) level , triglyceride ( TG ) level , glycated hemoglobin ( HbA1c ) level , blood clot use International Normalized Ratio ( INR ) , creatinine per milliliter ( Cr/ml ) , random blood sugar ( RBG ) . Patients control group treat 180µg pegylated IFN ( Pegasys-Roche ) subcutaneously weekly three month . In addition , give ribavirin accord body weight ( 1200 mg 75 kg 1000 mg 75 kg ) . The Biobran group treat Biobran , dose 1g per day , allocate packet , take orally meal three month duration study . Biobran denature hemicellulose obtain react rice bran hemicellulose multiple carbohydrate hydrolyzing enzyme Shiitake mushroom . It polysaccharide contain ß-1 , 3-glucans , activate hemicellulose . Biobran kindly provide Daiwa Pharmaceuticals Co. Ltd. , Tokyo , Japan . The patient divide randomly two group : Biobran group PEG interferon plus ribavirin ( control ) group . Prior treatment , clinical characteristic determine patient group . The clinical characteristic HCV patient investigate hepatitis C , alpha-fetoprotein ( AFP ) level , total leucocyte count ( TLC ) , Platelet ( PLT ) count , Hemoglobin ( Hb ) level , triglyceride ( TG ) level , glycated hemoglobin ( HbA1c ) level , blood clot use International Normalized Ratio ( INR ) , creatinine per milliliter ( Cr/ml ) , random blood sugar ( RBG ) . Viral load level , toxicity , liver enzymes , γ-interferon ( IFN-γ ) level examine three month treatment . Viral load examine quantitative polymerase chain reaction ( PCR ) test use COBAS® TaqMan® Analyzer ( Roche Corporation ) . IFN-γ , AFP , ALT , AST level analyze use specific Elisa Kits , perform Spectrum Chemical Manufacturing Corporation , Gardena , CA , USA , toxicity assess questionnaire , physician observation , laboratory result .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Immunologic Factors</mesh_term>
	<criteria>Patients diagnose chronic HCV infection chronic active liver disease . Patients diagnose chronic HBV , HIV infection , autoimmune disorder , heart disease , kidney disease blood disease , neoplastic disorder . Pregnant lactate lady , drug abuser exclude .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Arabinoxylan</keyword>
	<keyword>HCV</keyword>
	<keyword>Viremia</keyword>
	<keyword>Biobran</keyword>
	<keyword>PEG interferon</keyword>
</DOC>